{"created":"2023-05-15T14:48:10.294337+00:00","id":66013,"links":{},"metadata":{"_buckets":{"deposit":"d87d6c14-22cc-45b0-9509-1b60b4c0fa6e"},"_deposit":{"created_by":1,"id":"66013","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"66013"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00066013","sets":["10:29"]},"author_link":["650059","650060","650058","650061"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2016-10-07","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT), the internal radiotherapy using radioisotope (RI)-labeled cancer specific antibody, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the alpha particle has high cell cytotoxicity and its short range can prevent damages to untargeted tissues. Astatine 211 (211At) is one of the useful alpha-RI. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with 211At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with 211At-trastuzumab as a new effective therapeutic for HER2+ PMGC.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要(会議名, 開催地, 会期, 主催者等)","attribute_value_mlt":[{"subitem_description":"第75回日本癌学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"650058","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"650059","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"李 惠子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"650060","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"650061","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-11-09"},"publish_date":"2016-11-09","publish_status":"0","recid":"66013","relation_version_is_last":true,"title":["HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:53:41.694411+00:00"}